ZimVie's stock has plunged over 40% since my downgrade, but recent cost reductions are improving profitability, and the stock is forming a bottoming pattern. Despite continued revenue declines, especially internationally, EBITDA margins have expanded and full-year guidance remains achievable. Valuation is now attractive, with ZIMV trading at a significant discount to dental implant peers on a Fwd EV/EBITDA basis.
ZIMV launches RealGUIDE Software Suite and Implant Concierge in Japan to boost digital dental workflows.
ZimVie Inc. (NASDAQ:ZIMV ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Webb Campbell - Investor Relations Vafa Jamali - President & Chief Executive Officer Richard Heppenstall - Chief Financial Officer Conference Call Participants Dylan Finley - UBS Anderson Schock - B. Riley Securities Matthew Miksic - Barclays Bank Operator Good afternoon, and welcome to ZimVie's First Quarter 2025 Earnings Conference Call.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJQ Thomas J. Queeney Piscataqua Savings Bank | 7 | $0.07 | $0.07 | - | - |
| MD Mike Damas MARYLAND CAPITAL ADVISORS Inc. | 4 | $0.05 | $0.04 | -$0.01 | -20% |
| NH Nadine Hofstetter Northwest Bank & Trust Co. | 8 | $89 | $88.96 | -$0.04 | -0.04% |
| - Industry | - Sector | Vafa Jamali CEO | NASDAQ (NGS) Exchange | 98888T107 CUSIP |
| US Country | 1,770 Employees | - Last Dividend | - Last Split | 1 Mar 2022 IPO Date |
ZimVie Inc. is a medical technology company that has swiftly positioned itself as a leader in the development, manufacturing, and delivery of medical products and solutions addressing a gamut of health needs globally. With a specific focus on spine pathologies and dental procedures, ZimVie Inc. caters to a wide range of medical disciplines through an extensive portfolio of innovative products. Incorporated in 2021, the company has established its headquarters in Westminster, Colorado, indicating a strategic positioning in the United States for its global operations.